RE: deal with Immunodiagnostic2 Nov 2017 16:59
Possibly though the new CEO may be a bit more of a go getter? And actually move things on �. we can but hope.
Nonetheless I feel the big prize and possibly nearer term is commercialisation of Visitect CD4. Company still confident of CE mark before end of calendar year. I understand we will also require a WHO prerequisite to clear the way for large orders but, with the links to said organisation, and the urgent need, I expect that to happen quite quickly.